Rznomics Announces Major Advances in Circular RNA Production
Biopharmaceutical company Rznomics Inc. has reported a breakthrough in the high-efficiency production of circular RNA (circRNA), a key development for novel gene therapies.
Seongnam, South Korea – Rznomics Inc., a biopharmaceutical company, has announced a significant advancement in the production of circular RNA (circRNA). This development reportedly achieves high-efficiency production, a critical factor for the advancement of RNA-based gene therapies.
The company's new production method is said to significantly improve the efficiency and quality of circRNA. This improvement could accelerate the development of new treatments for various diseases. CircRNA has gained recent attention in research due to its stability and versatile applications.
Rznomics believes this breakthrough will enable the provision of enhanced RNA molecules for clinical and commercial use. The company's research and development efforts are particularly focused on the delivery of circRNA via exosomes.
The company continues its research and development activities, aiming to further refine its production processes and expand the applications of its RNA technology.